After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Drug Manufacturers – Specialty & Generic industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $2.80 and fluctuated between $2.9150 as its day high and $2.7100 as its day low. The current market capitalization of Organogenesis Holdings Inc is $369.49M. A total of 0.71 million shares were traded on the day, compared to an average of 669.86K shares.
In the most recent transaction, ERANI ALBERT sold 17,972 shares of ORGO for 4.28 per share on Jan 10 ’24. After the transaction, the 10% Owner now owns 59,007,134 company shares. In a previous transaction on Jan 10 ’24, ERANI ALBERT sold 17,972 shares at 4.28 per share. ORGO shares that 10% Owner owns now total 59,007,134.
Among the insiders who sold shares, ERANI ALBERT disposed of 197,921 shares on Jan 09 ’24 at a per-share price of $4.37. This resulted in the 10% Owner holding 59,025,106 shares of ORGO after the transaction. In another insider transaction, ERANI ALBERT sold 197,921 shares at $4.37 per share on Jan 09 ’24. Company shares held by the 10% Owner now total 59,025,106.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, ORGO has a high of $4.70 and a low of $1.79.
As of this writing, ORGO has an earnings estimate of -$0.03 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.01 per share and a lower estimate of -$0.04.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ORGO’s latest balance sheet shows that the firm has $113.93M in Cash & Short Term Investments as of fiscal 2021. There were $132.30M in debt and $82.70M in liabilities at the time. Its Book Value Per Share was $2.12, while its Total Shareholder’s Equity was $241.34M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ORGO is Buy with a score of 4.33.
